Cidara Therapeutics, Inc. Aktie News

Cidara Therapeutics, Inc. ( CDTX ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Jeffrey Stein - President, CEO & Executive Director Nicole Davarpanah - Chief Medical Officer Shane Ward - COO & Corporate Secretary Les Tari - Chief Scientific Officer Jim Beitel - Chief Business Officer Conference Call Participants Brian Ritchie - Lifesci Advisors, LLC Maxwell Skor - Mor...

Announced expanded and accelerated Phase 3 Plan for CD388, its non-vaccine influenza preventative therapeutic Enrolled and dosed first patients in Phase 3 ANCHOR study; target enrollment on track for completion in the Northern Hemisphere by December 2025; Phase 3 initiation triggered $45.0 million milestone payment to Janssen BARDA award to support expanded manufacturing and clinical developmen...

SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below November investor conferences.

SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its third quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, November 6, 2025. The Compan...

SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it gave a late-breaking presentation on its non-vaccine influenza preventative candidate, CD388, at the European Scientific Working Group on Influenza (ESWI)'s 10th Influenza Con...

Cidara's CD388 is a novel flu prophylactic designed for universal prevention of seasonal and pandemic influenza through a single dose, with potential to be the new standard-of-care. Phase 2 data showed efficacy of 78% for the highest dose, well ahead of traditional vaccines. Accelerated Phase 3 enrollment, with interim analysis in March 2026 and data readout expected around June 2026.

SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it presented late-breaking Phase 2b clinical data on its non-vaccine influenza preventative candidate, CD388, during ID Week 2025, taking place October 19-22, 2025, in Atlanta...

SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will be presenting late-breaking Phase 2 clinical data on its antiviral influenza candidate, CD388, during ID Week 2025, taking place October 19-22, 2025, in Atlanta, GA. P...